PT93264A - Processo para a preparacao de hidrazina bifuncional ou de derivados de hidrazina de conjugados que os contem e de macromoleculas marcadas com ioes metalicos - Google Patents

Processo para a preparacao de hidrazina bifuncional ou de derivados de hidrazina de conjugados que os contem e de macromoleculas marcadas com ioes metalicos

Info

Publication number
PT93264A
PT93264A PT93264A PT9326490A PT93264A PT 93264 A PT93264 A PT 93264A PT 93264 A PT93264 A PT 93264A PT 9326490 A PT9326490 A PT 9326490A PT 93264 A PT93264 A PT 93264A
Authority
PT
Portugal
Prior art keywords
hydrazine
bifunctional
macromolecules
marked
preparation
Prior art date
Application number
PT93264A
Other languages
English (en)
Other versions
PT93264B (pt
Inventor
Michael J Abrams
David A Schwartz
Christen M Giandomenico
Jon A Zubieta
Original Assignee
Johnson Matthey Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey Inc filed Critical Johnson Matthey Inc
Publication of PT93264A publication Critical patent/PT93264A/pt
Publication of PT93264B publication Critical patent/PT93264B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paints Or Removers (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)
PT93264A 1989-02-24 1990-02-23 Processo para a preparacao de hidrazina bifuncional ou de derivados de hidrazina de conjugados que os contem e de macromoleculas marcadas com ioes metalicos PT93264B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31527089A 1989-02-24 1989-02-24

Publications (2)

Publication Number Publication Date
PT93264A true PT93264A (pt) 1990-08-31
PT93264B PT93264B (pt) 1996-01-31

Family

ID=23223639

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93264A PT93264B (pt) 1989-02-24 1990-02-23 Processo para a preparacao de hidrazina bifuncional ou de derivados de hidrazina de conjugados que os contem e de macromoleculas marcadas com ioes metalicos

Country Status (18)

Country Link
EP (1) EP0384769B1 (pt)
JP (1) JP3073997B2 (pt)
KR (1) KR0142079B1 (pt)
AT (1) ATE137219T1 (pt)
AU (1) AU630668B2 (pt)
CA (1) CA2010800C (pt)
DE (1) DE69026637T2 (pt)
DK (1) DK0384769T3 (pt)
ES (1) ES2085890T3 (pt)
FI (1) FI95907C (pt)
GR (1) GR3019758T3 (pt)
HU (1) HU207293B (pt)
IE (1) IE74849B1 (pt)
IL (1) IL93432A (pt)
NO (1) NO178186C (pt)
NZ (2) NZ232656A (pt)
PT (1) PT93264B (pt)
ZA (1) ZA901283B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
US6001979A (en) * 1989-08-29 1999-12-14 Nycomed Amersham Plc Cores for technetium radiopharmaceuticals
US5589576A (en) * 1989-08-29 1996-12-31 Amersham International Plc Cores for technetium radiopharmaceuticals
US5296599A (en) * 1991-09-19 1994-03-22 Millipore Corporation Activated carbamates compounds
GB9209641D0 (en) * 1992-05-02 1992-06-17 Johnson Matthey Plc Improvements in radiolabelling
GB9223168D0 (en) * 1992-11-05 1992-12-16 Johnson Matthey Plc Improvements in molecule labelling
US5750088A (en) * 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
AU7261994A (en) * 1993-07-19 1995-02-20 Resolution Pharmaceuticals Inc. Hydrazino-type radionuclide chelators having an n3s configuration
US5753206A (en) * 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
US7102024B1 (en) 2000-08-01 2006-09-05 Schwartz David A Functional biopolymer modification reagents and uses thereof
US6686461B1 (en) 2000-03-22 2004-02-03 Solulink Bioscience, Inc. Triphosphate oligonucleotide modification reagents and uses thereof
AU2001247697B2 (en) 2000-03-22 2006-06-22 Solulink, Incorporated Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP5137814B2 (ja) 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート
CN102978185B (zh) 2007-01-18 2015-02-11 建新公司 包含氨基氧基基团的寡糖及其轭合物
EP3608330B1 (en) 2008-12-16 2022-11-09 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57181058A (en) * 1981-04-30 1982-11-08 Ikeda Mohandou:Kk Compound labeled with 99m technetium, and its preparation
US4861869A (en) * 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
DE3728599A1 (de) * 1986-12-10 1988-06-23 Hoechst Ag Verfahren zur herstellung einer mit technetium-99m-markierten organspezifischen substanz
US5066490A (en) * 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles

Also Published As

Publication number Publication date
NO900838D0 (no) 1990-02-22
ES2085890T3 (es) 1996-06-16
NZ232656A (en) 1992-04-28
PT93264B (pt) 1996-01-31
CA2010800A1 (en) 1990-08-24
HUT53600A (en) 1990-11-28
IE74849B1 (en) 1997-08-13
NZ239288A (en) 1992-04-28
DE69026637T2 (de) 1996-09-26
HU900970D0 (en) 1990-05-28
EP0384769A2 (en) 1990-08-29
DK0384769T3 (da) 1996-05-13
NO900838L (no) 1990-08-27
NO178186C (no) 1996-02-07
CA2010800C (en) 2001-01-16
KR900012910A (ko) 1990-09-03
IL93432A (en) 1994-02-27
FI900948A0 (fi) 1990-02-23
NO178186B (no) 1995-10-30
HU207293B (en) 1993-03-29
EP0384769B1 (en) 1996-04-24
GR3019758T3 (en) 1996-07-31
JPH0327356A (ja) 1991-02-05
KR0142079B1 (ko) 1998-06-01
ATE137219T1 (de) 1996-05-15
AU5007490A (en) 1990-09-13
ZA901283B (en) 1991-03-27
EP0384769A3 (en) 1991-11-27
JP3073997B2 (ja) 2000-08-07
FI95907B (fi) 1995-12-29
IE900666L (en) 1990-08-24
FI95907C (fi) 1996-04-10
AU630668B2 (en) 1992-11-05
DE69026637D1 (de) 1996-05-30

Similar Documents

Publication Publication Date Title
FI95907B (fi) Proteiinin merkkaus
Evans et al. Mechanism for cadmium and zinc antagonism of copper metabolism
HU914133D0 (en) Linking molecules being to split off by means of acids
PT97639A (pt) Processo para a preparacao de hidrazinas n-substituidas bifuncionais e de composicoes farmaceuticas que as contem
US4888415A (en) Gelonin immunotoxin
DK5982A (da) Fremgangsmaade til fremstilling af immunoglobulinkonjagater
PT98831A (pt) Processo para a preparacao de pro-medicamentos de derivados de fenilalanina e fenetilamina n-substituidos com cicloalquilo e policicloalquilo beta-substituidos com triptofano e de composicoes farmaceuticas que os contem
MA21204A1 (fr) Nouveau derive d'azole, procede pour le preparer et composition chimique pour l'agriculture et l'horticulture le contenant.
Haskins et al. Tubulin assembly induced by cobalt and zinc
TONOMURA et al. Removal of bound nucleotide and calcium of G-actin by treatment with ethylenediaminetetraacetic acid
Allaben et al. The purification of rat liver arylhydroxamic acid N, O-acyltransferase.
PT92952A (pt) Processo para a preparacao de acidos 3-fenil-5,6-di-hidrobenz { c }acridina-7- carboxilicos, de compostos relacionados e de composicoes farmaceuticas que os contem
Lee et al. Inactivation of phosphorylase b by potassium ferrate. Identification of a tyrosine residue involved in the binding of adenosine 5'-monophosphate
Thach et al. The binding of aminoacyl-sRNA's to ribosomes stimulated by block oligonucleotides.
US5144009A (en) Conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, their use as immunotoxin potentiators and the intermediate activated inophores
Rayshell et al. Evidence that N-acetoxy-N-acetyl-2-aminofluorene crosslinks DNA to protein by a free radical mechanism
PT85316B (pt) Processo para a obtencao de uma glicoproteina inibidora da sintese proteica
GEP19991535B (en) Process for the Preparation of 7-Hydroxy Taxanes
Abakumova et al. Effect of N-methyl-N-nitrosourea on the protein-synthesizing system in mouse liver and hepatoma 22a cells
DE59408321D1 (de) Verfahren zur Herstellung von Isopropylidenderivaten von Sacchariden
EP0235116A2 (de) Desaktivierte Proteinderivate
Laidler et al. The controlled disulphide crosslinking of difeerent proteins as a method for synthesis of combined protein antigens and copolymers of other design
Ehrlich et al. The site and stoichiometry of the N-phenylmaleimide reaction with myosin when weakly-binding crossbridges are formed in skinned rabbit psoas fibers
Yunusova et al. Conformational changes of gossypulin in solutions at various pH values influence of salts
Cumber et al. Preparation of Cytotoxic Antibody—Toxin Conjugates

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19951017

PC3A Transfer or assignment

Free format text: 19990517 ANORMED INC. CA